TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Drug Liking Emax
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Motivation and Confidence in Physical Activity
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Desire to Participate in Physical Activity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Healthy Food Knowledge
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: estimated GFR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Global Hyperemic Myocardial Blood Flow (MBF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in parent behavior
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Change in child communication and social engagement
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Change in Cervical pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Cervical discapacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Solicited Local Injection Site Reactions by Severity
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Solicited Systemic Adverse Events (AEs) by Severity
Endpoint domain: Adverse events/effects
Primary endpoint: Geometric Mean Titers (GMTs) of Neutralizing Antibody for Zika Virus (ZIKV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: accuracy of TEP's to determine the nature of an ovarian tumor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: accuracy of ctDNA to determine the nature of an ovarian tumor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: accuracy of ctDNA to predict treatment response in ovarian cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: vascular changes in macular vasculature
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Area Under Curve (AUC) of Average Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of BMT-i
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of BMT-i
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Antiviral efficacy by HIV RNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mid upper Arm Circumference (MUAC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immunogenicity assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Titer of ADA positive sample
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Therapeutic Efficacy A
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Therapeutic Efficacy B
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of continent patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in serum interleukin 21
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Fruits and Vegetables
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in saturated fats
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in added sugar
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Adherence Rate to Antiretroviral Therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Transition From Acute to Chronic Low Back Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in vital signs (e.g., blood pressure)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with higher gastric pH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Proportion of patients with dose limiting toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Buccal bone width (BBW)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Soft tissue thickness (STT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of dose-limiting toxicities (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Percentage From Baseline in Success of Penetration (SEP2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Closure of the greater saphenous vein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: p-HER2 and p-MET status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MET-N375S mRNA copy number
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Identification of MET and TP53 mutations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Asthma control level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Clearance of Viral Shedding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: 1-year Post-induction Disease-free Survival (DFS) Rate
Endpoint domain: Mortality/survival
Primary endpoint: 24-hour peri-operative mortality rate
Endpoint domain: Mortality/survival
Primary endpoint: Change in Modified Ashworth at 12 Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in Range of Motion at 12 Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Amsterdam Preoperative Anxiety and Information Scale (APAIS) SCORE
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of Study Related Complications Experienced
Endpoint domain: Adverse events/effects
Primary endpoint: Return to Usual Major Activity and Work Productivity
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Malaria confirmed by microscopy
Endpoint domain: Adverse events/effects
Primary endpoint: Pneumonia confirmed by chest x-ray
Endpoint domain: Adverse events/effects
Primary endpoint: Safety of the proposed treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Community Participation
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Change in perceived stress levels
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: WOMAC Knee and Hip Osteoarthritis Index
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in ki-67 expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in histological markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum tolerated doses (MTD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Treatment-emergent Creatine Phosphokinase (CPK) Elevations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Participants With Elevated Serum Creatinine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Number of Patients That Experienced Dose Limiting Toxicity From ABT-751
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Patients That Achieved Complete Response to ABT-751
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Restoration of endocrine disturbances
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Magnitude of HIV-specific CD4+ and CD8+ T-cell responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Safety (local and systemic reactogenicity signs and symptoms, laboratory measures, and adverse and serious experiences)
Endpoint domain: Adverse events/effects
Primary endpoint: Social impact
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Improvement on the MRS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alive and Free of Organ Failure at Day 28
Endpoint domain: Mortality/survival
Primary endpoint: Changes in venous blood pH
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of subjects achieving SVR12
Endpoint domain: Mortality/survival
Primary endpoint: Induced apoptosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Blood Carbon Monoxide levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in LVEF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Aesthetic Improvement at Week 3
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Aesthetic Improvement at Week 6
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Aesthetic Improvement at Week 9
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Annualised joint bleeding rate (AJBR) for treated bleeds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Taste Reward Brain Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Food Choice Brain Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Brain Activation and Food Intake Relationships
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Stiffness Index scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Heightened Sensitivity scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Healed rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disease rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radial artery diameter and blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Ulnar artery diameter and blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: MADRS Change at Day 7
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Durations of motor block
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Lower Extremity Fugl-Meyer Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median morphine milligram equivalents (MME) per opioid prescription
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of orders for balanced intravenous (IV) fluid solutions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in Swelling
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in Itching Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reintubation rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percentage of healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Grade 4 TMI Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With 1 Year Mortality Unrelated to TMI
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of Participants That Achieved Symptomatic Remission at Week 6
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in Bowel Inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Changes in microvascular blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Rate of immunization in patients over 75 years old
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Seroconversion for Anti-pertussis Toxoid and Anti-filamentous Hemagglutinin Antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants With Seroprotection for Anti-Hepatitis B, Anti-Polyribosyl Ribitol Phosphate (PRP), Anti-Tetanus, Anti-Diphtheria, and Anti-Polio Antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Geometric Mean Titers of Anti-Tetanus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Geometric Mean Titers of Anti-Polio Types 1, 2, and 3 Antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Postanesthesia care unit (PACU) admission duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self reported VAS pain scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Pain perception during burn wound care
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of inflammatory markers (IL-6 and TNFα)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: C-terminal telopeptide of type I collagen (CTX)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: HBeAg / Anti-HBe Seroconversion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total antimicrobial consumption
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Safety of FV-100
Endpoint domain: Adverse events/effects
Primary endpoint: Pharmacokinetics of FV-100 and CF-1743
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cystic cavity area reduction efficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in Suicidality as assessed by the Columbia-Suicide Severity Rating Scale (CSSRS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Adverse events (AEs) including frequency and severity
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum Concentration of LY2603618 in the Plasma (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Concentration of Desipramine in the Plasma (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration Versus Time Curve From Time Zero to Infinity [AUC(0-∞)] for LY2603618
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration Versus Time Curve From Time Zero to Infinity [AUC(0-∞)] for Desipramine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measurement of AMH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Sensitivity of ECG for Acute Coronary Occlusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Specificity of ECG for Acute Coronary Occlusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from baseline in mobility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Pancreatic Neuroendocrine Tumors (PNET)
Endpoint domain: Mortality/survival
Primary endpoint: Change in Urinary % Monomethyl Arsenic
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Urinary % Inorganic Arsenic
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Urinary % Dimethyl Arsenic
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants With Treatment Emergent Adverse Events (TEAEs) Categorized by Severity
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Toxicity or Intolerable Dose Criteria
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Positive Anti-Drug-Antibodies (ADA) and Neutralizing Antibodies (Nab)
Endpoint domain: Adverse events/effects
Primary endpoint: Compliance to the diet
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Manageability of the diet
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Identification of intervention group
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change of Aniseikonia tolerance after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum levels of IL-2, IL-4, IL-6, IL-10, TNF-ɑ, IFN-γ
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Popliteal test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of asymptomatic subjects
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive CD4 and CD8 cell epitope positive response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Natural Killer Cell Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Cytokine Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Perceived Stress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Sleep
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Number of Participants With Treatment-Emergent Adverse Events (All Causalities)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Serious Adverse Events (All Causalities and Palbociclib-Related)
Endpoint domain: Adverse events/effects
Primary endpoint: triceps muscle thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: triceps and biceps strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: triceps and biceps endurance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Pegfilgrastim C[Max]
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pegfilgrastim AUC[0-infinity]
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: E[Max] for Baseline Non-adjusted ANC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUEC[0-t] for Baseline Non-adjusted ANC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endothelial Dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Microvascular Dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Diffuse Plaque
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change from baseline Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Percentage of Patients With a Clinical Response (CDAI Decrease of ≥70 Compared With Baseline)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse events associated with CDX-1127 administration
Endpoint domain: Adverse events/effects
Primary endpoint: Successful Thoracic Epidural Catheter Placement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Technical success of the MR-guided cryoablation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Safety of the MR-guided cryoablation
Endpoint domain: Adverse events/effects
Primary endpoint: Short term tumor recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in Cognitive function
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Psychiatric function
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Post-traumatic stress syndrome
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Regional brain gamma-aminobutyric acid (GABA) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Regional brain glutamate metabolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Regional brain neuronal integrity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: myocardial stiffness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of SARS-CoV-2
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Who Achieved a ≥ 1-Stage Improvement in Fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Aldosterone Increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Venham's clinical rating scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: British Isles Lupus Assessment Group (BILAG) disease activity index Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes